Show simple item record

dc.contributor.authorFankhauser, Christian Daniel
dc.contributor.authorOldenburg, Jan
dc.contributor.authorAlbers, Peter
dc.contributor.authorAlgaba, Ferran
dc.contributor.authorBokemeyer, Carsten
dc.contributor.authorBoormans, Joost L.
dc.contributor.authorFischer, Stefanie
dc.contributor.authorFizazi, Karim
dc.contributor.authorGremmels, Hendrik
dc.contributor.authorMayor de Castro, Javier
dc.contributor.authorJanisch, Florian
dc.contributor.authorMuilwijk, Tim
dc.contributor.authorLeao, Ricardo
dc.contributor.authorNicol, David
dc.contributor.authorNicolai, Nicola
dc.contributor.authorTandstad, Torgrim
dc.contributor.authordel Pilar Laguna Pes, Maria
dc.date.accessioned2021-08-02T08:52:49Z
dc.date.available2021-08-02T08:52:49Z
dc.date.issued2021en_US
dc.identifier.citationFankhauser, C. D., Oldenburg, J., Albers, P., Algaba, F., Bokemeyer, C., Boormans, J. L. ... del Pilar Laguna Pes, M. (2021). Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. European Urology, 80(1), 4-6. https://dx.doi.org/10.1016/j.eururo.2021.02.032en_US
dc.identifier.issn0302-2838
dc.identifier.issn1873-7560
dc.identifier.urihttps://dx.doi.org/10.1016/j.eururo.2021.02.032
dc.identifier.urihttps://hdl.handle.net/20.500.12511/7641
dc.description.abstractRecent randomized controlled trials have assessed the risksand benefits of thromboprophylaxis in ambulatory cancerpatients receiving chemotherapy and reported a relativerisk reduction of 30–60% in venous thromboembolic events(VTEs) but a doubling of bleeding risk [1–4]. Based on theseresults, the most recent American Society of ClinicalOncology clinical practice guideline update recommendsthromboprophylaxis with apixaban, rivaroxaban, or low-molecular–weight heparin (LMWH) for cancer patientswith a high risk of VTE and low risk of bleeding [5]. Patientswith metastatic germ-cell tumor (mGCT) were under-represented in all trials and thus it is not clear whether thisrecommendation applies to this group, although retrospec-tive data suggests similar efficacy of VTE prophylaxis.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectBalance Benefitsen_US
dc.subjectRisks of Thromboprophylaxisen_US
dc.subjectMetastatic Germ Cell Tumorsen_US
dc.subjectEuropean Association Of Urology Testicular Cancer Panel Position in 2021en_US
dc.titleRecommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021en_US
dc.typeeditorialen_US
dc.relation.journalEuropean Urologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalıen_US
dc.authorid0000-0003-0906-4417en_US
dc.identifier.volume80en_US
dc.identifier.issue1en_US
dc.identifier.startpage4en_US
dc.identifier.endpage6en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.1016/j.eururo.2021.02.032en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record